drugset / Trial / NCT04836806

Cetirizine and Famotidine for COVID-19

NCT04836806

Phase 4 Withdrawn Emory University
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cetirizine and famotidine in reducing the duration of symptoms in patients with COVID-19. Secondary aims are to determine if cetirizine and famotidine decrease severity and duration of symptoms, incidence of hospitalizations, ICU admissions, and death.

Timeline

Start
2021-08
Primary completion
2022-07
Completion
2022-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetirizine Other / unclassified 10 mg
Subject Famotidine Other / unclassified 20 mg

Indications